Development of a novel vaccine for Zika

June 5, 2017, American Society for Microbiology
Transmission electron microscope image of negative-stained, Fortaleza-strain Zika virus (red), isolated from a microcephaly case in Brazil. The virus is associated with cellular membranes in the center. Credit: NIAID

Research presented by Farshad Guirakhoo, Ph.D., Chief Scientific Officer, GeoVax, Inc., at the ASM Microbe 2017 meeting showed a new Zika virus vaccine that gives 100% protection in mice. The vaccine is the first to be based on the Zika virus NS1 protein, and the first to show single-dose protection against Zika in an immunocompetent lethal mouse challenge model. Results of the study were presented on June 4 at the American Society for Microbiology (ASM) Microbe conference in New Orleans.

The rapid spread of Zika virus worldwide and its association with abnormal fetal brain development has made the need for an effective clear. Controlling the mosquito vector and protecting people against mosquito bites have been the main means of defending against Zika virus infections.

The viral vector vaccine technology developed by GeoVax uses a highly potent, safe, and replication-deficient viral vector (Modified Vaccinia Ankara, MVA) to express vaccine antigens in the recipient's cells. It has previously been used to develop for HIV and Ebola virus. The vaccine, from GeoVax Labs, Inc. in Atlanta, Ga., was tested at the Centers for Disease Control and Prevention (CDC) in Ft. Collins, Colo., with funding by a grant from the CDC.

In the presented study, outbred immunocompetent mice were exposed to a lethal challenge dose of Zika virus delivered directly into the brain. "A single dose of GeoVax's NS1 vaccine candidate protected 100% of vaccinated animals," said Guirakhoo. In contrast, 80-90% of sham-immunized control animals died within 7-10 days.

Because the NS1 antigen is not presented on the surface of the virus, it was chosen as the target immunogen for the vaccine to avoid a potential risk of disease enhancement when vaccines are developed based on Zika virus envelope proteins. This "Antibody Dependent Enhancement (ADE) of infection" phenomena has been shown between Zika virus and a related flavivirus, Dengue, in both in vitro and in vivo studies.

An NS1-based vaccine could also limit or block transmission of Zika virus in its mosquito vector. The NS1 protein is abundantly produced by flaviviruses in infected hosts and is picked up together with the virus after the mosquito takes a blood meal from humans. The NS1 proteins interfere with the innate immune system of the mosquito, evolved to fight foreign pathogens, allowing the flavivirus to replicate and disseminate in mosquitoes. Therefore, said Guirakhoo, "a vaccine that can induce effective antibodies to NS1 and disable its function has the potential to reduce growth and transmission of Zika in its mosquito vector. This could enhance in endemic areas by blocking the from infected individuals to other members of the community."

Explore further: Translational research leads to potential Zika virus vaccine

Related Stories

Translational research leads to potential Zika virus vaccine

May 10, 2017
Preclinical results of research by City College of New York scientists and TechnoVax, Inc. in animal models demonstrate favorable outcomes in developing a vaccine against the mosquito-borne Zika virus. The results were announced ...

India confirms first Zika virus cases: WHO

May 27, 2017
The Indian health ministry has confirmed its first cases of the Zika virus, the World Health Organisation has said, the latest nation to be affected by the mosquito-borne virus that sparked global concern.

The first live-attenuated vaccine candidate completely protects mice against Zika infection

April 10, 2017
The first live-attenuated Zika vaccine still in the development stage completely protected mice against the virus after a single vaccination dose, according to new research from The University of Texas Medical Branch at Galveston ...

More evidence that Zika mRNA vaccines can stop viral replication in mice

February 17, 2017
Vaccine developers have successfully protected mice against Zika by injecting synthetic messenger RNA that encodes for virus proteins into the animals. The cells of the mice then build parts of the virus, training the immune ...

Discovery of a Zika antibody offers hope for a vaccine

May 4, 2017
A research team based at The Rockefeller University has identified a potent new weapon against the Zika virus in the blood of people who have been infected by it. This discovery could lead to new ways of fighting the disease, ...

Traces of Zika Found in Asian tiger mosquito in Brazil

April 14, 2017
In a recent test of Asian tiger mosquitoes collected in Brazil, researchers found fragments of Zika virus RNA, raising concerns that it may be carried by species other than Zika's known primary vector, the yellow fever mosquito.

Recommended for you

Infants born to obese mothers risk developing liver disease, obesity

November 16, 2018
Infant gut microbes altered by their mother's obesity can cause inflammation and other major changes within the baby, increasing the risk of obesity and non-alcoholic fatty liver disease later in life, according to researchers ...

New study shows NKT cell subsets play a large role in the advancement of NAFLD

November 16, 2018
Since 2015 it has been known that the gut microbiota could have a direct impact on nonalcoholic fatty liver disease (NAFLD), which affects up to 12% of adults and is a leading cause of chronic liver disease. In the November ...

Antibiotic prescribing influenced by team dynamics within hospitals

November 15, 2018
Antibiotic prescribing by doctors is influenced by team dynamics and cultures within hospitals.

Discovery suggests new route to fight infection, disease

November 14, 2018
New research reveals how a single protein interferes with the immune system when exposed to the bacterium that causes Legionnaires' disease, findings that could have broad implications for development of medicines to fight ...

Zika may hijack mother-fetus immunity route

November 14, 2018
To cross the placenta, Zika virus may hijack the route by which acquired immunity is transferred from mother to fetus, new research suggests.

New research aims to help improve uptake of hepatitis C testing

November 14, 2018
New research published in Scientific Reports shows persisting fears about HIV infection may impact testing uptake for the hepatitis C Virus (HCV).

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.